CONCORDANCE BETWEEN MISSED DAYS OF HEPATITIS B VIRUS ANTI-VIRAL THERAPY AND VIROLOGICAL BREAKTHROUGH

Sheppard-Law S,1,2,3, Kermeen M4, Holdaway S5, George J6,7, Zekry A7,8, Dore G1, Zablotska-Manos I1, Maher L1

The Kirby Institute, UNSW Australia 1, Sydney Children’s Hospital Network, Australia 2, University of Technology, Sydney, Australia 3, Concord Repatriation General Hospital, Concord Australia 4, Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW Australia 5, Westmead Clinical School, University of Sydney, Westmead Australia 6, St George Hospital, Department of Gastroenterology & Hepatology, Kogarah, Australia 7 St George Hospital Clinical Group School of Medicine, UNSW Australia 8

Background

Adherence to treatment is imperative to achieve and maintain suppression of the hepatitis B virus (HBV). To date, there has been limited research on what defines adherence to HBV therapies. Our study aimed to investigate the relationship between missed days of anti-viral therapy and HBV DNA virological breakthrough.

Methods

In 2014 277 patients receiving anti-viral therapies in three Sydney tertiary hospitals completed a cross-sectional survey. Data were excluded from analyses if participants reported factors known to affect HBV DNA viral suppression (n=66) or if HBV virology results were not available (n=7). Self-reported non-adherence was assessed as 0 to > 6 single days of treatment missed and 2 to 6 consecutive days missed in the last 30 days. Associations between missed days and virological breakthrough (defined as > 10-fold rise in serum HBV DNA above nadir or after achieving virological response in the last 12 months) were examined to determine the level of non-adherence most strongly associated with virological breakthrough. Associations were summarised as odds ratios (OR) and relative risks (RR).

Results

Of the 204, 32 participants (15.6%) had quantifiable HBV DNA levels (> 20 IU/mL), with 15 (46.8%) of these participants experiencing virological breakthrough. Participants reported never missing medication (n=130, 63.7%), missing one day (n=23, 11.3%), missing > one day (n=23, 11.3%) and missing >2-6 days (n=15, 7.3%) and missing >6 days (n=13, 6.4%). The most discriminating definition of non-adherence was missing > one day of medication (RR=8.3; OR=10.2, 95%CI: 3.1-33.8, p≤0.001, ROC 0.76) and sensitivity and specificity of detecting the outcome of 73.3% and 78.8%.

Conclusion

This study produced an evidence-based definition of non-adherence that informs clinical practice, in that patients reporting missing >1 day of medication in the previous 30 days have an increased risk of virological breakthrough, and provides the basis for key patient education messages.